| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg | |||
| Other Sizes |
Purity: ≥98%
Vecabrutinib (formerly SNS-062; FP-182, BSK-4841 and BIIB-062) is a novel, potent, and reversible/noncovalent BTK and ITK inhibitor with Kd of 0.3 nM and 2.2 nM, respectively; Vecabrutinib shows an IC50 of 24 nM for ITK. SNS-062 does not require interaction with BTK C481 for inhibitory activity. SNS-062 has improved PK properties over ibrutinib, including greater bioavailability and a longer half-life. SNS-062 may offer an alternative treatment option to patients with acquired resistance to ibrutinib.
| ln Vitro |
In human whole blood, vecabrutinib inhibits pBTK with a mean IC50 of 50 nM. Similar IC50 values (pBTK IC50: WT BTK 2.9 nM, C481S BTK 4.4 nM) are observed for vecabrutinib's inhibition of WT and C481S BTK [1]. Vecabrutinib's IC50 against WT BTK and C481S BTK in recombinant kinase assays was 4.6 nM and 1.1 nM, respectively. Vecabrutinib continues to be active against BTK mutant forms. Vecabrutinib demonstrated dose-dependent suppression of BTK similar to PCI-32765 in primary patient CLL cells via BTK phosphorylation immunoblotting. Vecabrutinib was six times more effective than PCI-32765 and more than 640 times more potent than acalabrutinib against C481S BTK. Vecabrutinib decreases primary CLL cell survival by 5.5% when HS5 stromal protection is present [2].
|
|---|---|
| ln Vivo |
In rats and dogs, vecabrutinib exhibits a good oral bioavailability (%F > 40%) with a terminal half-life of five to six hours. At doses and durations much beyond PCI-32765, vecabrutinib was well tolerated [1].
|
| References |
|
| Additional Infomation |
Vecabrutinib is being investigated in the clinical trial NCT03037645 (Safety, pharmacokinetics, pharmacodynamics, and antitumor activity of vecabrutinib (SNS-062) in B-cell lymphoma). Vecabrutinib is an orally administered, second-generation, reversible Bruton's tyrosine kinase (BTK; Bruton's agammaglobulinemia tyrosine kinase) inhibitor with potential antitumor activity. After administration, vecabrutinib non-covalently binds to and inhibits the activity of wild-type and C481S mutant BTK. The C481S mutation is a resistance mutation at the BTK active site in which serine residue 481 is replaced by cysteine. This prevents activation of the B-cell antigen receptor (BCR) signaling pathway and activation of BTK-mediated downstream survival pathways. This leads to the inhibition of the growth of malignant B cells that overexpress BTK. Compared to other BTK inhibitors, SNS-062 inhibits the proliferation of cells carrying the BTK C481S mutation without interacting with the BTK C481 site. Other irreversible BTK inhibitors inhibit BTK activity by covalently binding to the C481 site; the C481S mutation prevents this binding. BTK is a member of the Src-associated BTK/Tec family of cytoplasmic tyrosine kinases and is overexpressed in B-cell malignancies; it plays an important role in B lymphocyte development, activation, signal transduction, proliferation, and survival.
|
| Molecular Formula |
C22H24CLF4N7O2
|
|---|---|
| Molecular Weight |
529.918276786804
|
| Exact Mass |
529.161
|
| CAS # |
1510829-06-7
|
| Related CAS # |
1270014-40-8 (SNS062-analog);1510829-06-7; 1947403-49-7;
|
| PubChem CID |
72547837
|
| Appearance |
White to light yellow solid powder
|
| Density |
1.5±0.1 g/cm3
|
| Boiling Point |
776.0±60.0 °C at 760 mmHg
|
| Flash Point |
423.1±32.9 °C
|
| Vapour Pressure |
0.0±2.7 mmHg at 25°C
|
| Index of Refraction |
1.621
|
| LogP |
3.13
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
11
|
| Rotatable Bond Count |
5
|
| Heavy Atom Count |
36
|
| Complexity |
809
|
| Defined Atom Stereocenter Count |
3
|
| SMILES |
C1C[C@H](C(=O)N(C1)[C@H]2CN(CC[C@@H]2C(=O)N)C3=NC=NC(=C3F)N)NC4=CC(=CC(=C4)C(F)(F)F)Cl
|
| InChi Key |
QLRRJMOBVVGXEJ-XHSDSOJGSA-N
|
| InChi Code |
InChI=1S/C22H24ClF4N7O2/c23-12-6-11(22(25,26)27)7-13(8-12)32-15-2-1-4-34(21(15)36)16-9-33(5-3-14(16)19(29)35)20-17(24)18(28)30-10-31-20/h6-8,10,14-16,32H,1-5,9H2,(H2,29,35)(H2,28,30,31)/t14-,15+,16-/m0/s1
|
| Chemical Name |
(3R,3'R,4'S)-1'-(6-amino-5-fluoropyrimidin-4-yl)-3-[3-chloro-5-(trifluoromethyl)anilino]-2-oxo[1,3'-bipiperidine]-4'-carboxamide
|
| Synonyms |
SNS-062; SNS 062; SNS062; BSK-4841; BSK4841; BSK 4841; FP182; FP 182; FP-182; BIIB-062; BIIB062; BIIB 062
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~125 mg/mL (~235.88 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (4.72 mM) (saturation unknown) in 5% DMSO + 40% PEG300 + 5% Tween80 + 50% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (4.72 mM) (saturation unknown) in 5% DMSO + 95% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.08 mg/mL (3.93 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution. Solubility in Formulation 4: ≥ 2.08 mg/mL (3.93 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Solubility in Formulation 5: ≥ 2.08 mg/mL (3.93 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.8871 mL | 9.4354 mL | 18.8708 mL | |
| 5 mM | 0.3774 mL | 1.8871 mL | 3.7742 mL | |
| 10 mM | 0.1887 mL | 0.9435 mL | 1.8871 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA